Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021
November 08, 2021 08:00 ET
|
Neurona Therapeutics
IND cleared by the FDA to enable initiation of Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant focal epilepsy Supporting preclinical data demonstrate seizure-freedom in up to 68%...
Former U.S. Congressman Fattah Calls for African Brain Research Fund During Global Neuroscience Conference
October 28, 2021 17:57 ET
|
Fattah Neuroscience Global Advisors
Accra, Ghana / Philadelphia, PA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Today, former United States Congressman and CEO of Fattah Neuroscience Global Advisors, Chaka Fattah, delivered a powerful virtual...
Nexstim’s SmartFocus® TMS Technology Used in Award-Winning Project Addressing Disorders of Consciousness after Severe Brain Injury
October 15, 2021 02:00 ET
|
Nexstim Oyj
Press release, Helsinki, 15 October 2021 at 9 AM (EEST) Nexstim’s SmartFocus® TMS Technology Used in Award-Winning Project Addressing Disorders of Consciousness after Severe Brain Injury Nexstim Plc...
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
September 10, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris,...
Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training
July 21, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
London, UK – 21 July 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)
July 07, 2021 12:51 ET
|
Ischemix, Inc.
GRAFTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Ischemix, Inc., a private company focused on developing therapeutics for serious medical conditions, today announced that the US Department of...
COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme
June 23, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
Programme aims to support students from under-represented ethnic groups London, UK – 23 June 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to...
Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum
April 29, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...
Sensory Challenges and Anxiety in Children with and without Autism - A Free Webinar from the Brain & Behavior Research Foundation
March 02, 2021 09:00 ET
|
Brain & Behavior Research Foundation
New York, March 02, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Sensory Challenges and Anxiety in Children with and without Autism” on...
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
February 16, 2021 13:23 ET
|
Novartis International AG
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction...